Home » ISIS PHARMACEUTICALS BEGINS DEVELOPMENT PROGRAM FOR ISIS 301012
ISIS PHARMACEUTICALS BEGINS DEVELOPMENT PROGRAM FOR ISIS 301012
Isis Pharmaceuticals has initiated the development program of ISIS 301012 in patients with familial hypercholesterolemia (FH), a genetic disorder that causes extremely high cholesterol levels and results in the early-onset of heart disease.
The Phase II studies in patients with FH are part of a broad Phase II development program of ISIS 301012. ISIS 301012, a second-generation antisense drug, reduces levels of apoB-100, a protein critical to the synthesis and transport of the "bad" cholesterol involved in heart disease -- low-density lipoprotein cholesterol and very low-density lipoprotein. Lowering cholesterol levels is a key component in the prevention and management of cardiovascular disease.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May